Essex Woodlands Management, Inc. - Q3 2013 holdings

$151 Million is the total value of Essex Woodlands Management, Inc.'s 11 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 0.0% .

 Value Shares↓ Weighting
ABMD  ABIOMED INC$60,039,000
-11.6%
3,150,0000.0%39.64%
-23.8%
ELGX  ENDOLOGIX INC$34,034,000
+119.9%
1,165,4280.0%22.47%
+89.5%
ACUR  ACURA PHARMACEUTICALS INC$18,840,000
+0.7%
10,294,8860.0%12.44%
-13.3%
HZNP  HORIZON PHARMA INC$18,012,000
+37.1%
5,815,9400.0%11.89%
+18.1%
ZIOP  ZIOPHARM ONCOLOGY INC$9,721,000
+79.6%
2,764,9080.0%6.42%
+54.7%
CO  CHINA CORD BLOOD CORP$3,943,000
+35.3%
1,037,6900.0%2.60%
+16.6%
MNOV  MEDICINOVA INC$3,007,000
-2.3%
1,170,3700.0%1.99%
-15.8%
SLTM  SOLTA MED INC$2,753,000
-9.2%
1,330,2190.0%1.82%
-21.8%
CRIS  CURIS INC$1,043,000
+40.0%
233,7970.0%0.69%
+20.7%
ECTE  ECHO THERAPEUTICS INC$34,000
+9.7%
12,3190.0%0.02%
-8.3%
PTN  PALATIN TECHNOLOGIES INC$17,000
+21.4%
23,9280.0%0.01%0.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2013-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MEDICINOVA INC42Q3 20236.5%
REVANCE THERAPEUTICS INC39Q3 202344.6%
AXOGEN INC26Q4 202143.3%
ENDOLOGIX INC24Q1 201922.5%
ABIOMED INC20Q1 201852.1%
CORIUM INTL INC20Q1 201923.5%
TELA BIO, INC.16Q3 202331.5%
VENUS CONCEPT, INC.16Q3 202321.3%
ACURA PHARMACEUTICALS INC15Q1 20191.4%
CATALYST BIOSCIENCES INC15Q1 20191.0%

View Essex Woodlands Management, Inc.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-15

View Essex Woodlands Management, Inc.'s complete filings history.

Compare quarters

Export Essex Woodlands Management, Inc.'s holdings